Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

11.79
+0.10000.86%
Volume:101.08K
Turnover:1.19M
Market Cap:383.88M
PE:-12.65
High:11.96
Open:11.69
Low:11.46
Close:11.69
Loading ...

NeuroPace reports sees Q4 revenue $21M-$21.5M, consensus $20.91M

TIPRANKS
·
09 Jan

NeuroPace narrows FY24 revenue view to $79.4M-$79.9M from $78M-$80M

TIPRANKS
·
09 Jan

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

GlobeNewswire
·
09 Jan

Institutions profited after NeuroPace, Inc.'s (NASDAQ:NPCE) market cap rose US$37m last week but private equity firms profited the most

Simply Wall St.
·
08 Jan

NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
26 Dec 2024

Positive Outlook for NeuroPace: Anticipated Success of NAUTILUS Study and Strategic Market Advantage

TIPRANKS
·
21 Dec 2024

NeuroPace Is Maintained at Overweight by JP Morgan

Dow Jones
·
18 Dec 2024

NeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market with Promising Long-Term Growth

TIPRANKS
·
17 Dec 2024

NeuroPace price target raised to $14 from $9 at JPMorgan

TIPRANKS
·
17 Dec 2024

U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart

Reuters
·
17 Dec 2024

NeuroPace to Host Investor Day on January 28th in New York City

GlobeNewswire
·
13 Dec 2024

Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet

Zacks
·
06 Dec 2024

NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting

GlobeNewswire
·
05 Dec 2024

BRIEF-Neuropace Completes Enrollment In Feasibility Study Of Rns System

Reuters
·
04 Dec 2024

Neuropace Completes Enrollment in Feasibility Study of Rns System for Lennox-Gastaut Syndrome

THOMSON REUTERS
·
04 Dec 2024

NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome

GlobeNewswire
·
04 Dec 2024

Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements

TIPRANKS
·
22 Nov 2024

What Makes NeuroPace (NPCE) a New Buy Stock

Zacks
·
19 Nov 2024

NeuroPace Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Nov 2024

NeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy Rating

TIPRANKS
·
14 Nov 2024